TARDBP and neurodegenerative disease: Neurodegenerative diseases can be classified according to the anatomic distribution of the neurodegeneration (e.g., frontotemporal degenerations, extrapyramidal disorders, or spinocerebellar degenerations) or the principal molecular abnormality (e.g., amyloidoses, tauopathies, α-synucleinopathies, and transactive response DNA binding protein of 43 kDa (TDP-43) proteinopathies) or, most commonly, according to their clinical presentations [1].